Wockhardt Ltd
Wockhardt Ltd Q3 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on Wockhardt Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Net Sales Revenues for 9M FY24: INR 2,129 Cr. EBITDA for the quarter (9M FY24) is INR 173 Cr, showing a 7% growth year-on-year.
From Wockhardt Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Net Sales Revenues for 9M FY24: INR 2,129 Cr. with 7% growth (Page 6)
- EBITDA for 9M FY24: INR 173 Cr. (Page 6)
- 9M FY24 Vaccine sales show an 80% growth (Page 6)
- International Business accounts for 78% of 9M FY24 sales revenue (Page 4)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vaccine Supply & Collaboration agreement with Serum Life Sciences Limited:
- Profit sharing 51:49 favoring Wockhardt
- 15-year arrangement
- Reserved capacity of 150 million doses per annum
- Facility located in the UK
- Diabetes Biosimilars manufacturing infrastructure:
- Manufacturing infrastructure ready for Human Insulin & Insulin Glargine
- Pipeline includes Aspart R & Aspart Mix under PK/PD development stage
- Registered or under registration in over 40 markets; low-cost manufacturing with own patented delivery device
- Biotechnology facilities:
- 4 drug substance manufacturing facilities
- 2 drug product manufacturing facilities
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹965 Cr, net profit ₹164 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key investor presentation takeaways from NGL Fine
- Anuh Pharma Ltd (Q3 FY24)
172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key investor presentation takeaways from Anuh Pharma Ltd's Q3 FY24 investor pres
- Bharat Parenterals Ltd (Q3 FY24)
Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key investor presentation takeaways from Bharat Parenterals Ltd's Q3 FY24 investor presentation — and how
- Themis Medicare Ltd (Q3 FY24)
82.51 Cr, down 7.06% year-on-year from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY24 investor presentation — and how it ranks again
Frequently Asked Questions
What were Wockhardt Ltd Q3 FY24 results?
Net Sales Revenues for 9M FY24: INR 2,129 Cr. EBITDA for the quarter (9M FY24) is INR 173 Cr, showing a 7% growth year-on-year.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
Vaccine Supply & Collaboration agreement with Serum Life Sciences Limited: - Profit sharing 51:49 favoring Wockhardt - 15-year arrangement - Reserved capacity of 150 million doses per annum -
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.